Overview
Blautia wexlerae is a strictly anaerobic, Gram-positive bacterium belonging to the family Lachnospiraceae within the phylum Firmicutes. It is the dominant Blautia species in the human gut and has been particularly well-studied in Japanese populations, where it shows strong inverse correlations with obesity and type 2 diabetes. Research suggests that B. wexlerae may exert its beneficial effects through the production of specific bioactive metabolites including S-adenosylmethionine, acetylcholine, and L-ornithine, which have anti-adipogenic and anti-inflammatory properties.
Classification
B. wexlerae belongs to the genus Blautia within the Lachnospiraceae family, a diverse taxonomic group of SCFA-producing anaerobes. It is closely related to Blautia obeum and other Blautia species that collectively play important roles in gut carbohydrate fermentation and metabolite cross-feeding. The genus Blautia was established after reclassification of several species formerly placed in Ruminococcus and other genera, and now contains over a dozen recognized species.
Key Characteristics
B. wexlerae is notable for producing a specific set of bioactive metabolites — S-adenosylmethionine, acetylcholine, and L-ornithine — that have been identified as active molecules in reducing adipogenesis and inflammation. The species also participates in microbial cross-feeding networks by supplying succinate, lactate, and acetate to downstream SCFA producers such as Butyricicoccus and other butyrate-producing bacteria. In preclinical models, oral administration reduced M1-like macrophage infiltration in visceral adipose tissue, suggesting a direct anti-inflammatory mechanism in fat tissue. Systematic reviews of the Blautia genus found beneficial associations in 97.2% of obesity-related studies examined.
Health Significance
A large human cohort study (217 discovery + 195 validation participants) confirmed that B. wexlerae is inversely correlated with both BMI and type 2 diabetes, with the association holding regardless of age, sex, or metformin use. Preclinical administration to high-fat-diet mice produced significant reductions in obesity and diabetes markers through metabolic remodeling and anti-inflammatory effects. More recent research has also suggested that B. wexlerae may protect against altitude-induced hypoxic damage to lungs and intestines. While these findings are promising, most evidence comes from observational human cohort studies and animal models; randomized controlled trials in humans are needed to confirm therapeutic potential and establish optimal dosing strategies.